202 related articles for article (PubMed ID: 22217686)
1. [Novel oral anticancer drugs: a review of adverse drug reactions, interactions and patient adherence].
Bartal A; Mátrai Z; Szucs A; Belinszkaja G; Langmár Z; Rosta A
Orv Hetil; 2012 Jan; 153(2):66-78. PubMed ID: 22217686
[TBL] [Abstract][Full Text] [Related]
2. Oral targeted therapies: managing drug interactions, enhancing adherence and optimizing medication safety in lymphoma patients.
Liewer S; Huddleston AN
Expert Rev Anticancer Ther; 2015 Apr; 15(4):453-64. PubMed ID: 25683755
[TBL] [Abstract][Full Text] [Related]
3. Drug interactions in metastatic breast cancer.
Tyler T
J Oncol Pharm Pract; 2011 Sep; 17(3):236-45. PubMed ID: 20861179
[TBL] [Abstract][Full Text] [Related]
4. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology.
Foulon V; Schöffski P; Wolter P
Acta Clin Belg; 2011; 66(2):85-96. PubMed ID: 21630604
[TBL] [Abstract][Full Text] [Related]
5. Adherence to oral cancer therapies: nursing interventions.
Winkeljohn D
Clin J Oncol Nurs; 2010 Aug; 14(4):461-6. PubMed ID: 20682501
[TBL] [Abstract][Full Text] [Related]
6. Oral administration of antineoplastic agents: the challenges for healthcare professionals.
Tadic D; Spasojevic IB; Tomasevic ZI; Dejanovic SD
J BUON; 2015; 20(3):690-8. PubMed ID: 26214619
[TBL] [Abstract][Full Text] [Related]
7. Oral Anticancer Therapy: Management of Drug Interactions.
Rogala BG; Charpentier MM; Nguyen MK; Landolf KM; Hamad L; Gaertner KM
J Oncol Pract; 2019 Feb; 15(2):81-90. PubMed ID: 30763198
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
9. Anticancer oral therapy: emerging related issues.
Banna GL; Collovà E; Gebbia V; Lipari H; Giuffrida P; Cavallaro S; Condorelli R; Buscarino C; Tralongo P; Ferraù F
Cancer Treat Rev; 2010 Dec; 36(8):595-605. PubMed ID: 20570443
[TBL] [Abstract][Full Text] [Related]
10. Guiding pharmacist clinical interviews: a safety tool to support the education of patients treated with oral antineoplastic agents.
Ribed A; Escudero-Vilaplana V; Romero-Jimenez RM; Iglesias-Peinado I; Herranz-Alonso A; Sanjurjo-Saez M
Expert Opin Drug Saf; 2016; 15(4):427-35. PubMed ID: 26854363
[TBL] [Abstract][Full Text] [Related]
11. A review on adherence management in patients on oral cancer therapies.
Wood L
Eur J Oncol Nurs; 2012 Sep; 16(4):432-8. PubMed ID: 22051845
[TBL] [Abstract][Full Text] [Related]
12. Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents.
Gebbia V; Bellavia G; Ferraù F; Valerio MR
Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S49-59. PubMed ID: 22149481
[TBL] [Abstract][Full Text] [Related]
13. Large-scale automatic extraction of side effects associated with targeted anticancer drugs from full-text oncological articles.
Xu R; Wang Q
J Biomed Inform; 2015 Jun; 55():64-72. PubMed ID: 25817969
[TBL] [Abstract][Full Text] [Related]
14. Outcome Assessments and Cost Avoidance of an Oral Chemotherapy Management Clinic.
Wong SF; Bounthavong M; Nguyen CP; Chen T
J Natl Compr Canc Netw; 2016 Mar; 14(3):279-85. PubMed ID: 26957614
[TBL] [Abstract][Full Text] [Related]
15. Adherence and patients' experiences with the use of oral anticancer agents.
Timmers L; Boons CC; Kropff F; van de Ven PM; Swart EL; Smit EF; Zweegman S; Kroep JR; Timmer-Bonte JN; Boven E; Hugtenburg JG
Acta Oncol; 2014 Feb; 53(2):259-67. PubMed ID: 24266637
[TBL] [Abstract][Full Text] [Related]
16. Oral Anticancer Medication Adherence, Toxicity Reporting, and Counseling: A Study Comparing Health Care Providers and Patients.
Gandhi S; Day L; Paramsothy T; Giotis A; Ford M; Boudreau A; Pasetka M
J Oncol Pract; 2015 Nov; 11(6):498-504. PubMed ID: 26395564
[TBL] [Abstract][Full Text] [Related]
17. New Oral Anti-Cancer Drugs and Medication Safety.
Schlichtig K; Dürr P; Dörje F; Fromm MF
Dtsch Arztebl Int; 2019 Nov; 116(46):775-782. PubMed ID: 31920193
[TBL] [Abstract][Full Text] [Related]
18. Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists.
Regnier Denois V; Poirson J; Nourissat A; Jacquin JP; Guastalla JP; Chauvin F
Eur J Cancer Care (Engl); 2011 Jul; 20(4):520-7. PubMed ID: 20649809
[TBL] [Abstract][Full Text] [Related]
19. Adherence to oral endocrine treatments in women with breast cancer: can it be improved?
Doggrell SA
Breast Cancer Res Treat; 2011 Sep; 129(2):299-308. PubMed ID: 21594663
[TBL] [Abstract][Full Text] [Related]
20. Are patients on oral chemotherapy in your practice setting safe?
Moody M; Jackowski J
Clin J Oncol Nurs; 2010 Jun; 14(3):339-46. PubMed ID: 20529795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
